UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Elevated GM3 plasma concentration in idiopathic Parkinson's disease: A lipidomic analysis

PloS one, 2017-02, Vol.12 (2), p.e0172348-e0172348

2017

Volltextzugriff (PDF)

Analysis of Heterozygous PRKN Variants and Copy‐Number Variations in Parkinson's Disease

Movement disorders, 2021-01, Vol.36 (1), p.178-187

2021

Volltextzugriff (PDF)

SCARB2 variants and glucocerebrosidase activity in Parkinson's disease

NPJ Parkinson's Disease, 2016-03, Vol.2 (1), p.16004, Article 16004

2016

Volltextzugriff (PDF)

The Clinical Development of Levodopa Inhalation Powder

Clinical neuropharmacology, 2023-03, Vol.46 (2), p.66

2023

Volltextzugriff (PDF)

A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson's disease

Parkinsonism & related disorders, 2020-12, Vol.81, p.144-150

2020

Volltextzugriff (PDF)

Impaired Perception of Vocal Emotions in Parkinson's Disease: Influence of Speech Time Processing and Executive Functioning

Brain and cognition, 2001-03, Vol.45 (2), p.277-314

2001

Volltextzugriff (PDF)

Gene-based burden analysis of damaging private variants in PRKN, PARK7 and PINK1 in Parkinson's disease cohorts of European descent

Neurobiology of aging, 2022-11, Vol.119, p.136-138

2022

Volltextzugriff (PDF)

Continuous dopaminergic delivery to minimize motor complications in Parkinson's disease

Expert review of neurotherapeutics, 2013-06, Vol.13 (6), p.719-729

2013

Volltextzugriff (PDF)

Long-Term Treatment with Extended-Release Carbidopa–Levodopa (IPX066) in Early and Advanced Parkinson’s Disease: A 9-Month Open-Label Extension Trial

CNS drugs, 2015-04, Vol.29 (4), p.341-350

2015

Volltextzugriff (PDF)

Current strategies in the treatment of Parkinson's disease and a personalized approach to management

Expert review of neurotherapeutics, 2009-12, Vol.9 (12), p.1781-1789

2009

Volltextzugriff (PDF)

Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3-month, randomized, placebo-controlled study

Movement disorders, 2004-04, Vol.19 (4), p.426-432

2004

Volltextzugriff (PDF)

Analysis of common and rare VPS13C variants in late-onset Parkinson disease

Neurology. Genetics, 2020-02, Vol.6 (1), p.385-385

2020

Volltextzugriff (PDF)

Knowledge of and Interest in Genetic Results Among Parkinson Disease Patients and Caregivers

Journal of genetic counseling, 2014-02, Vol.23 (1), p.114-120

2014

Volltextzugriff (PDF)

Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy

Neurology. Clinical practice, 2017-02, Vol.7 (1), p.86-93

2017

Volltextzugriff (PDF)

Applause sign in clinically overlapping diseases: A case of TDP-43 proteinopathy

Parkinsonism & related disorders, 2013-08, Vol.19 (8), p.774-775

2013

Volltextzugriff (PDF)

Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease

Journal of clinical and experimental neuropsychology, 2010-08, Vol.32 (7), p.775-779

2010

Volltextzugriff (PDF)

Increased rate of sporadic and recurrent rare genic copy number variants in Parkinson's disease among Ashkenazi Jews

Molecular genetics & genomic medicine, 2013-09, Vol.1 (3), p.142-154

2013

Volltextzugriff (PDF)

Treatment of advanced stage patients with Parkinson's disease

Parkinsonism & related disorders, 2002-10, Vol.9 (1), p.15-21

Waters, Cheryl H

2002

Volltextzugriff (PDF)

A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit

JAMA neurology, 2014-05, Vol.71 (5), p.543

2014

Volltextzugriff (PDF)

Transdermal dopaminergic D2 receptor agonist therapy in Parkinson's disease with N-0923 TDS: A double-blind, placebo-controlled study

Movement disorders, 2001-05, Vol.16 (3), p.459-463

2001

Volltextzugriff (PDF)

Pharmacologic management of Parkinson disease: Treatment of levodopa-associated "wearing off"

Formulary (Cleveland, Ohio), 2006-08, Vol.41, p.12

Waters, Cheryl H

2006

Volltextzugriff (PDF)

Increased rate of sporadic and recurrent rare genic copy number variants in P arkinson's disease among A shkenazi J ews

Molecular genetics & genomic medicine, 2013-09, Vol.1 (3), p.142-154

2013

Volltextzugriff (PDF)

Pharmacologic Options for Treatment of Levodopa-Associated ``Wearing Off

Journal of pharmacy practice, 2008-08, Vol.21 (4), p.254-261

2008

Volltextzugriff (PDF)

Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease

Archives of neurology (Chicago), 2009-12, Vol.66 (12), p.1517

2009

Volltextzugriff (PDF)

1 – 25 von 79

Suche als RSS-Feed

Aktive Filter

KollektionOxford Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(67)
Mit Volltextzugriff
(52)

Publikationsform

Sprache

Englisch
(79)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Science & Technology
(60)
Life Sciences & Biomedicine
(56)
Humans
(50)
Neurosciences & Neurology
(40)
Clinical Neurology
(37)
Parkinson's Disease
(33)
Female
(30)
Middle Aged
(30)
Biological And Medical Sciences
(29)
Medical Sciences
(29)
Male
(27)
Aged
(26)
Neurology
(22)
Parkinson Disease - Genetics
(19)
Adult
(16)
Parkinson Disease - Drug Therapy
(16)
Age Of Onset
(10)
Antiparkinson Agents - Adverse Effects
(10)
Mutation
(10)
Parkinson Disease - Physiopathology
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Elevated GM3 plasma concentration in idiopathic Parkinson's disease: A lipidomic analysis

Analysis of Heterozygous PRKN Variants and Copy‐Number Variations in Parkinson's Disease

SCARB2 variants and glucocerebrosidase activity in Parkinson's disease

The Clinical Development of Levodopa Inhalation Powder

A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson's disease

Impaired Perception of Vocal Emotions in Parkinson's Disease: Influence of Speech Time Processing and Executive Functioning

Gene-based burden analysis of damaging private variants in PRKN, PARK7 and PINK1 in Parkinson's disease cohorts of European descent

Continuous dopaminergic delivery to minimize motor complications in Parkinson's disease

Long-Term Treatment with Extended-Release Carbidopa–Levodopa (IPX066) in Early and Advanced Parkinson’s Disease: A 9-Month Open-Label Extension Trial

Cognitive and motor function in long-duration PARKIN-associated Parkinson disease

Current strategies in the treatment of Parkinson's disease and a personalized approach to management

Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3-month, randomized, placebo-controlled study

Analysis of common and rare VPS13C variants in late-onset Parkinson disease

Knowledge of and Interest in Genetic Results Among Parkinson Disease Patients and Caregivers

Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy

Applause sign in clinically overlapping diseases: A case of TDP-43 proteinopathy

Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease

Increased rate of sporadic and recurrent rare genic copy number variants in Parkinson's disease among Ashkenazi Jews

Treatment of advanced stage patients with Parkinson's disease

A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit

Transdermal dopaminergic D2 receptor agonist therapy in Parkinson's disease with N-0923 TDS: A double-blind, placebo-controlled study

Pharmacologic management of Parkinson disease: Treatment of levodopa-associated "wearing off"

Increased rate of sporadic and recurrent rare genic copy number variants in P arkinson's disease among A shkenazi J ews

Pharmacologic Options for Treatment of Levodopa-Associated ``Wearing Off

Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease

Aktive Filter

Suchergebnisse filtern